A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...

The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under ...

Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...

Dr. Marla Lipsyc-Sharf reviews her recent session at the 2024 SABCS meeting, discussing biopsy approaches and treatment ...

A 40-year-old woman who was denied a life-extending cancer drug because it is not available in Wales has died.Rachel Davies, ...

The number of U.S. women with breast cancer that has spread elsewhere in the body by the time of diagnosis increased ...

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...

This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...